European Journal of Clinical Pharmacology

, Volume 69, Issue 10, pp 1747–1755 | Cite as

Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study

  • L. Frankenstein
  • H. A. Katus
  • M. Grundtvig
  • T. Hole
  • J. de Blois
  • D. Schellberg
  • D. Atar
  • C. Zugck
  • S. Agewall
  • on behalf of the Norwegian Heart Failure Registry steering committee
Clinical Trial

Abstract

Purpose

Heart failure (CHF) guidelines recommend mineralocorticoid receptor antagonists for all symptomatic patients treated with a combination of ACE inhibitors/angiotensin receptor blockers (ARBs) and beta-blockers. As opposed to both eplerenone trials, patients in RALES (spironolactone) received almost no beta-blockers. Since pharmacological properties differ between eplerenone and spironolactone, the prognostic benefit of spironolactone added to this baseline combination therapy needs clarification.

Methods

We included 4,832 CHF patients with chronic systolic dysfunction from the Norwegian Heart Failure Registry and the heart failure outpatients’ clinic of the University of Heidelberg. Propensity scores for spironolactone receipt were calculated for each patient and used for matching to patients without spironolactone.

Results

During a total follow-up of 17,869 patient-years, 881 patients (27.0 %) died in the non-spironolactone group and 445 (28.4 %) in the spironolactone group. Spironolactone was not associated with improved survival, neither in the complete sample (HR 0.82; 95 % CI 0.64–1.07; HR 1.03; 95 % CI 0.88–1.20; multivariate and propensity score adjusted respectively), nor in the propensity-matched cohort (HR 0.98; 95 % CI 0.82–1.18).

Conclusion

In CHF outpatients we were unable to observe an association between the use of spironolactone and improved survival when administered in addition to a combination of ACE/ARB and beta-blockers.

Keywords

Chronic heart failure Spironolactone Mineralocorticoid receptor antagonists Beta-blocker Survival Mortality benefit Combination therapy 

References

  1. 1.
    McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787–1847PubMedCrossRefGoogle Scholar
  2. 2.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14):e391–e479PubMedCrossRefGoogle Scholar
  3. 3.
    Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21. doi:10.1056/NEJMoa1009492 PubMedCrossRefGoogle Scholar
  4. 4.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309–1321. doi:10.1056/NEJMoa030207 PubMedCrossRefGoogle Scholar
  5. 5.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717. doi:10.1056/NEJM199909023411001 PubMedCrossRefGoogle Scholar
  6. 6.
    Pitt B (2009) Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction. Eur Heart J 30(4):387–388PubMedCrossRefGoogle Scholar
  7. 7.
    Sanchez-Mas J, Turpin MC, Lax A, Ruiperez JA, Valdes Chavarri M, Pascual-Figal DA (2010) Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in vitro. Rev Esp Cardiol 63(7):779–787PubMedCrossRefGoogle Scholar
  8. 8.
    Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M (2010) Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure. Am Heart J 160(5):915–921PubMedCrossRefGoogle Scholar
  9. 9.
    Frankenstein L, Remppis A, Fluegel A, Doesch A, Katus HA, Senges J, Zugck C (2010) The association between long-term longitudinal trends in guideline adherence and mortality in relation to age and sex. Eur J Heart Fail 12(6):574–580PubMedCrossRefGoogle Scholar
  10. 10.
    Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29(19):2388–2442PubMedCrossRefGoogle Scholar
  11. 11.
    Rubin DB (2004) On principles for modeling propensity scores in medical research. Pharmacoepidemiol Drug Saf 13(12):855–857. doi:10.1002/pds.968 PubMedCrossRefGoogle Scholar
  12. 12.
    Love TE (2009) Using propensity scores: stratification, adjustment, sensitivity and strategies. http://www.chrp.org/propensity/. Accessed 4 June 2005
  13. 13.
    Austin PC (2009) Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J 51(1):171–184. doi:10.1002/bimj.200810488 PubMedCrossRefGoogle Scholar
  14. 14.
    Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, Pitt B (2007) A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 28(11):1334–1343PubMedCrossRefGoogle Scholar
  15. 15.
    Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, McNeil BJ (2001) Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 54(4):387–398PubMedCrossRefGoogle Scholar
  16. 16.
    Rosenbaum PR (2002) Observational studies, 2nd edn. Springer, Berlin HeidelbergCrossRefGoogle Scholar
  17. 17.
    Love TE (2008) Spreadsheet-based sensitivity analysis calculations for matched samples. Center for Health Care Research & Policy, Case Western Reserve University, ClevelandGoogle Scholar
  18. 18.
    Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351(6):543–551. doi:10.1056/NEJMoa040135 PubMedCrossRefGoogle Scholar
  19. 19.
    Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM (2010) Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 340:c1768. doi:10.1136/bmj.c1768 PubMedCrossRefGoogle Scholar
  20. 20.
    Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM (2005) Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998–2001. Circulation 112(1):39–47. doi:10.1161/CIRCULATIONAHA.104.527549 PubMedCrossRefGoogle Scholar
  21. 21.
    Ko DT, Juurlink DN, Mamdani MM, You JJ, Wang JT, Donovan LR, Tu JV (2006) Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. J Card Fail 12(3):205–210. doi:10.1016/j.cardfail.2006.01.003 PubMedCrossRefGoogle Scholar
  22. 22.
    Ezekowitz JA, McAlister FA (2009) Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 30(4):469–477PubMedCrossRefGoogle Scholar
  23. 23.
    Fonarow GC, Alber NM, Curtis AB, Gheorghiade M, Liu Y, Mehra MR, O’Conor CM, Reynolds D, Walsh MN, Yancy CW (2012) Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case–control analysis of improve HF. J Am Heart Assoc 1:16–20. doi:10.1161/JAHA.111.000018 PubMedGoogle Scholar
  24. 24.
    Vizzardi E, D’Aloia A, Giubbini R, Bordonali T, Bugatti S, Pezzali N, Romeo A, Dei Cas A, Metra M, Dei Cas L (2010) Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol 106(9):1292–1296PubMedCrossRefGoogle Scholar
  25. 25.
    Berry C, Murphy NF, De Vito G, Galloway S, Seed A, Fisher C, Sattar N, Vallance P, Hillis WS, McMurray J (2007) Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail 9(4):429–434PubMedCrossRefGoogle Scholar
  26. 26.
    Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, Yamada S, Yokoshiki H, Takeshita A, Tsutsui H (2010) Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am Heart J 160(6):1156–1162PubMedCrossRefGoogle Scholar
  27. 27.
    Ouzounian M, Hassan A, Cox JL, Johnstone DE, Howlett J (2007) The effect of spironolactone use on heart failure mortality: a population-based study. J Card Fail 13(3):165–169PubMedCrossRefGoogle Scholar
  28. 28.
    Schuller S, Van Israel N, Vanbelle S, Clercx C, McEntee K (2011) Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs. J Vet Pharmacol Ther 34(4):322–331. doi:10.1111/j.1365-2885.2010.01235.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • L. Frankenstein
    • 3
    • 6
  • H. A. Katus
    • 3
  • M. Grundtvig
    • 4
  • T. Hole
    • 5
  • J. de Blois
    • 2
  • D. Schellberg
    • 3
  • D. Atar
    • 1
  • C. Zugck
    • 3
  • S. Agewall
    • 1
  • on behalf of the Norwegian Heart Failure Registry steering committee
    • 4
  1. 1.Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical SciencesUniversity of OsloOsloNorway
  2. 2.Centre Hospitalier Universitaire Affilié de QuébecQuebecCanada
  3. 3.University of HeidelbergHeidelbergGermany
  4. 4.Medical Department LillehammerLillehammerNorway
  5. 5.Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway & Medical ClinicHelse Møre and Romsdal HFÅlesundNorway
  6. 6.Department of Cardiology, Angiology, PulmonologyUniversity of HeidelbergHeidelbergGermany

Personalised recommendations